Chemotherapy remains the main treatment in locally advanced or metastatic lung cancer. The wide use of chemotherapy is often lengthy (4 months) and is not supported by any patient stratification tools, leading to life-threatening risk. Current techniques used to identify biomarkers for target or immunotherapy like Immunohistochemistry and Protein Ligase Assays have very low sensitivity (up to 30% of false negatives) resulting in qualitative, subjective measurements with poor prognostic value.
iaFRET is an imaging system based on a proprietary time resolved Amplified Forester Resonance Energy Transfer (FRET) technique. It determines both molecular and cell-cell interactions, enabling the evaluation of clinical efficiency of personalised cancer treatments. iaFRET enables oncologists to define the most effective treatment for each specific cancer case and verify its efficacy at any point during the therapy. Thus improving the prognosis and treatment selection of cancer patients and increasing their life expectancy.
Moreover iaFRET can lend itself to a variety of other emerging immunotherapy treatment procedures.
Fastbase Solutions S.L.